{"id":"tp-36102","type":"article-newspaper","title":"Rapport Therapeutics Shares Close 2.7% Higher on Phase 2 Results Day","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/36102","datePublished":"2026-10-20T23:26:08.000Z","dateModified":"2026-10-20T23:26:08.000Z","language":"en","abstract":"Monday’s 3.74% gain came before the announcement. RAP-219 met the primary and secondary endpoints in a three-week trial.","section":"Business","references":[{"title":"RAP-219’s Phase 2 trial results","url":"https://www.tokenpost.com/news/business/35833"}]}